Close

move up move left move right move bottom

Formulary Coverage

Comprehensive access support

Janssen is dedicated to making XARELTO® affordable and accessible for all patients. With widespread inclusion on hospital, managed care, and PBM formularies, >90% of commercial and Medicare patients are covered at the lowest branded co-pay.1

To see the coverage for your patients, enter your ZIP code. Your results will appear below.

Janssen CarePath Savings Card for XARELTO®

$0 co-pay every month* for patients with commercial insurance

  • Eligible patients with an approved chronic indication for XARELTO® (15 mg or 20 mg)

  • Per calendar year, subject to $3400 maximum annual program benefit. No monthly cap

For eligibility requirements and restrictions, visit Janssen CarePath or call 877-CarePath (877-227-3728). A Janssen CarePath Trial Offer for XARELTO® Trial Offer may also be available.

*Not valid for patients enrolled in Medicare Part D or Medicaid. Certain restrictions apply.

Janssen CarePath Trial Offer for XARELTO®

Assistance for patients with federally funded Medicare, Medicaid, TRICARE, or commercial insurance

  • Eligible patients with an approved chronic indication for XARELTO® (15 mg or 20 mg) will receive up to a free 30-day supply

  • Subject to 1 use or 12 months from program start date, whichever comes first

For eligibility requirements and restrictions, call 877-CarePath (877-227-3728).

Other Patient Assistance Resources

Assistance for patients with no insurance

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is committed to providing access to uninsured individuals who lack the financial resources to pay for their medicines.

If your patient needs XARELTO® and is uninsured and unable to pay for their medicine, and you would like to see if they might qualify for assistance, please have them:

  • contact a JJPAF program specialist at 1-800-652-6227, 9:00 AM-6:00 PM ET, or

  • visit the Foundation website

If a patient does not have coverage for XARELTO®, a comprehensive list of additional programs is available at Janssen Prescription Assistance.

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.

Reference:

  1. Data on file. Janssen Pharmaceuticals, Inc. Data as of November 2016.